药物辅助物. 药物辅助物. 是必要的,但并非无害的
Vicente Javier Baixauli-Fernández1
1Community pharmacist in Mislata (Valencia). President of SEFAC. Spain.
Farmaceuticos comunitarios
|March 6, 2026
概括
这封信评论了"药物辅助成分:必要但不无害"的文章,讨论了制药辅助剂在药物中的重要但潜在有害的作用.
科学领域:
- 制药科学 制药科学
- 药物的配方 药物的配方
背景情况:
- 药物辅助剂是制药配方的组成部分.
- 虽然辅助剂对于药物输送和稳定性至关重要,但它们可能具有固有的风险.
研究的目的:
- 为评论"药物辅助成分:必要但并非无害"这篇文章.
- 突出助剂的双重性质,即它们既是必要的,又是潜在的有害物质.
主要方法:
- 文学评论和对原始文章的批判性分析.
- 讨论助剂在制药实践中的使用影响.
主要成果:
- 助剂在药物产品的性能和患者安全方面发挥着至关重要的作用.
- 与常用的辅助剂相关的潜在不良影响和毒性需要仔细考虑.
结论:
- 选择和利用药物辅助剂需要一个平衡的方法.
- 需要进一步的研究和警,以减轻制药配方中的辅助剂的潜在危害.
相关概念视频
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
218
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
218
Factors Influencing Drug Absorption: Pharmaceutical Parameters
677
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
677
Pharmaceutical Equivalents
235
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
235
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
209
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
209
Site-Targeted Drug Delivery Systems: Polymeric Carriers
65
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
65
Modified-Release Drug Delivery Systems: Stimuli-Activated
58
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
58


